Amylyx Pharmaceuticals (AMLX) Cash & Equivalents (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Cash & Equivalents of $229.1 million for Q1 2026, up 283.4% year-over-year from $59.8 million in Q1 2025, and up 1.1% quarter-over-quarter from $226.7 million in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Cash & Equivalents (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Cash & Equivalents history runs 6 years deep, the most recent figure standing at $229.1 million for Q1 2026.
- In Q1 2026, Cash & Equivalents rose 283.4% year-over-year to $229.1 million; the TTM figure through Mar 2026 stood at $229.1 million (up 283.4% YoY), while the FY2025 annual figure was $226.7 million, up 192.86% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $229.1 million, up from $226.7 million in the prior quarter.
- The five-year high for Cash & Equivalents was $247.8 million in Q2 2023, with the low at $58.1 million in Q2 2025.
- The 5-year median for Cash & Equivalents is $110.4 million (2022), against an average of $130.0 million.
- The sharpest annual moves came in 2024 and 2026: Cash & Equivalents tumbled 69.73% in 2024, then surged 283.4% in 2026.
- Amylyx Pharmaceuticals' Cash & Equivalents stood at $62.5 million in 2022, then jumped by 172.21% to $170.2 million in 2023, then tumbled by 54.53% to $77.4 million in 2024, then soared by 192.86% to $226.7 million in 2025, then climbed by 1.1% to $229.1 million in 2026.
- Business Quant data shows AMLX's Cash & Equivalents at $229.1 million in Q1 2026, $226.7 million in Q4 2025, and $225.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 86.50 Bn | 85.53 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 42.71 Bn | 39.05 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 30.86 Bn | 29.18 Bn | 1.80 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.50 Bn | 22.70 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.06 Bn | 19.40 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.84 Bn | 17.95 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Vireo Growth | 11.86 Bn | 11.71 Bn | 59.30 Mn | 137.80 Mn |
| 9 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn | 530.00 Mn |
| 10 | Amylyx Pharmaceuticals | 3.91 Bn | 3.91 Bn | - | 49.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 49.33 Mn |
| Mar 31, 2026 | 229.14 Mn |
| Dec 31, 2025 | 226.65 Mn |
| Sep 30, 2025 | 225.18 Mn |
| Jun 30, 2025 | 58.09 Mn |
| Mar 31, 2025 | 59.76 Mn |
| Dec 31, 2024 | 77.39 Mn |
| Sep 30, 2024 | 71.84 Mn |
| Jun 30, 2024 | 75.00 Mn |
| Mar 31, 2024 | 170.55 Mn |
| Dec 31, 2023 | 170.20 Mn |
| Sep 30, 2023 | 135.26 Mn |
| Jun 30, 2023 | 247.76 Mn |
| Mar 31, 2023 | 114.56 Mn |
| Dec 31, 2022 | 62.53 Mn |
| Sep 30, 2022 | 107.73 Mn |
| Jun 30, 2022 | 67.44 Mn |
| Mar 31, 2022 | 110.40 Mn |
| Dec 31, 2021 | 50.19 Mn |